NEUROCRINE BIOSCIENCES INC — Director's Dealing 2017

Apr 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEUROCRINE BIOSCIENCES INC (NBIX)
CIK: 0000914475
Period of Report: 2017-04-12

Reporting Person: MOLLICA JOSEPH A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-04-12	Common Stock	M	20000	$3.40	Acquired	57354	Direct
2017-04-12	Common Stock	F	1312	$51.80	Disposed	56042	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-04-12	Stock Option	$3.40	M	20000	Disposed	2017-05-25	Common Stock (20000)	Direct

Footnotes

F1: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's Equity Incentive Plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($3.40) was subtracted from the April 12, 2017 market close price ($51.80), and this net amount ($48.40) was then multiplied by the number of options (20,000), with the resulting amount then divided by the market close price to result in a net issuance of 18,688 shares to the optionee. The 1,312 shares underlying the remaining portion of the options are not available for re-issuance, and no shares were sold into the market as a part of the exercise in connection with a net issuance program.